WITH THE EUROPEAN LAUNCH OF INSTANYL® - NYCOMED’S INTRANASAL FENTANYL SPRAY WHICH USES A VALOIS PHARMA VP7 PUMP - NASAL SPRAY IS CONFIRMED AS AN EFFECTIVE ROUTE FOR SYSTEMIC DELIVERY OF ACTIVE INGREDIENTS

World leader in nasal and pulmonary drug delivery devices, Valois Pharma worked closely with Nycomed to develop the spray device which allows fentanyl to be delivered intranasally for the first time to cancer patients suffering from breakthrough pain. As well as being non-invasive and easy-to-use, fentanyl delivered by nasal spray has fast onset of action.

A new step forward in systemic drug delivery via the nasal route

Estimated at 2 billion dollars in 2008, the world market for systemic drug delivery by the nasal route has seen strong growth in the last few years, with the launch of products such as those containing calcitonine for osteoporosis, desmopressine for enuresis and triptans for migraine attacks. Now Nycomed’s Instanyl® provides treatment for breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. These episodes of moderate to severe pain, which often are difficult to anticipate, can now be managed by patients themselves.

Systemic drug delivery by the nasal route has a number of advantages. After being sprayed into the nasal cavity and absorbed by the nasal mucosa, the medication enters the vascular system directly allowing the active ingredient to take effect rapidly. In addition, because it is easy to use, delivery by the nasal route allows the patient to have autonomous control over the treatment.

The VP7 spray pump - making drug delivery easier and improving patient comfort

Valois Pharma’s high-performance VP7 spray pump is widely used in drug delivery for both systemic and local treatment. For Instanyl®, Nycomed chose the VP7D version, which is designed to be used with preservative-free medication. The pump is fitted with a nasal actuator of ergonomic design that is comfortable to use. The VP7 range is recognized globally for its comfort of use by patients as well as for its total security coupled with excellent dose accuracy and spray performance.

Instanyl® is a registered trademark of Nycomed

Valois Pharma, a division of Valois S.A.S, specializes in nasal and pulmonary drug delivery technologies with a broad product range that also provides solutions for other drug delivery routes such as buccal/sub-lingual, throat and dermal/transdermal.

Valois S.A.S., founded in 1947, is a world leader in the design, development and manufacture of proprietary spray, aerosol and alternative dispensing systems for the Pharmaceutical, Perfumery and Cosmetics markets. Valois S.A.S. is a wholly owned subsidiary of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

Press contact:
Marie-Cécile Lachaux-Disle, press manager
Tel.: +33 (0)1 39 17 20 41 - Fax: +33 (0)1 39 58 12 98 - Email: mcld@valois.com

www.valoispharma.com